Han Koh

4.1k total citations · 3 hit papers
27 papers, 2.8k citations indexed

About

Han Koh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Han Koh has authored 27 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 5 papers in Genetics. Recurrent topics in Han Koh's work include Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (8 papers) and HER2/EGFR in Cancer Research (6 papers). Han Koh is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (8 papers) and HER2/EGFR in Cancer Research (6 papers). Han Koh collaborates with scholars based in United States, Spain and Japan. Han Koh's co-authors include George W. Sledge, Masakazu Toi, Norikazu Masuda, Xavier Pivot, Meena Okera, Joohyuk Sohn, Eva‐Maria Grischke, Peter A. Kaufman, Patrick Neven and Antonio Llombart‐Cussac and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Han Koh

26 papers receiving 2.8k citations

Hit Papers

MONARCH 2: Abemaciclib in Combination With Fulvestra... 2011 2026 2016 2021 2017 2011 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
    2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
  2. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    2011 807 citations Javier Cortés, Joyce O’Shaughnessy et al. The Lancet profile →
  3. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
    2019 590 citations George W. Sledge, Masakazu Toi et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Han Koh United States 12 2.2k 1.9k 866 529 304 27 2.8k
Nawel Bourayou United States 9 1.9k 0.8× 2.1k 1.1× 750 0.9× 560 1.1× 203 0.7× 25 2.4k
Janice M. Walshe Ireland 19 2.5k 1.1× 2.1k 1.1× 1.2k 1.3× 514 1.0× 414 1.4× 69 3.4k
Susana Barriga United States 13 2.9k 1.3× 3.3k 1.7× 1.2k 1.4× 920 1.7× 279 0.9× 26 3.7k
Katarína Petráková Czechia 23 2.1k 1.0× 1.4k 0.7× 989 1.1× 301 0.6× 645 2.1× 66 2.8k
Olga Burdaeva Russia 12 1.6k 0.7× 1.7k 0.9× 640 0.7× 465 0.9× 225 0.7× 27 2.1k
Meena Okera Australia 12 1.5k 0.7× 1.7k 0.9× 640 0.7× 492 0.9× 204 0.7× 32 2.0k
Martin Frenzel United States 14 3.2k 1.4× 3.7k 1.9× 1.3k 1.5× 998 1.9× 402 1.3× 28 4.1k
Binghe Xu China 26 2.4k 1.1× 1.0k 0.5× 1000 1.2× 256 0.5× 666 2.2× 149 3.1k
Gail S. Wright United States 13 2.7k 1.2× 1.1k 0.6× 817 0.9× 144 0.3× 720 2.4× 19 3.6k

Countries citing papers authored by Han Koh

Since Specialization
Citations

This map shows the geographic impact of Han Koh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Koh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Koh more than expected).

Fields of papers citing papers by Han Koh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Han Koh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Koh. The network helps show where Han Koh may publish in the future.

Co-authorship network of co-authors of Han Koh

This figure shows the co-authorship network connecting the top 25 collaborators of Han Koh. A scholar is included among the top collaborators of Han Koh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han Koh. Han Koh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Annie, et al.. (2023). Leukemic infiltration of the optic nerve in chronic lymphocytic leukemia: A case report and review of literature. Leukemia Research Reports. 20. 100391–100391. 2 indexed citations
2.
Grischke, Eva‐Maria, Antonio Llombart‐Cussac, Masakazu Toi, et al.. (2023). Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20(2). e5–e6. 1 indexed citations
3.
Llombart‐Cussac, Antonio, George W. Sledge, Masakazu Toi, et al.. (2023). Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Cancer Research. 83(5_Supplement). PD13–11. 11 indexed citations
4.
Koh, Han, SangJoon Lee, Hyo Lee, et al.. (2021). Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression. International Journal of Molecular Sciences. 22(23). 13136–13136. 39 indexed citations
5.
Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2021). MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer. Clinical Cancer Research. 27(21). 5801–5809. 7 indexed citations
6.
Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2020). MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 1061–1061. 2 indexed citations
7.
Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2019). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2. JAMA Oncology. 6(1). 116–116. 590 indexed citations breakdown →
8.
Parikh, Aparna R., Fa-Chyi Lee, Linda Yau, et al.. (2018). MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. Clinical Cancer Research. 25(10). 2988–2995. 39 indexed citations
9.
Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →
10.
Rashid, Nazia, et al.. (2017). Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system. Journal of Oncology Pharmacy Practice. 24(4). 253–263. 8 indexed citations
11.
Iwata, Hiroji, Petros Nikolinakos, J. Thaddeus Beck, et al.. (2017). Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2. Annals of Oncology. 28. v81–v82. 1 indexed citations
12.
Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Journal of Clinical Oncology. 35(15_suppl). 1000–1000. 10 indexed citations
13.
Rashid, Nazia, et al.. (2016). Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer Targets and Therapy. Volume 8. 173–181. 61 indexed citations
14.
Gettinger, Scott, Sen Zhang, John Hodgson, et al.. (2016). Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.. Journal of Clinical Oncology. 34(15_suppl). 9060–9060. 16 indexed citations
15.
Rashid, Nazia, et al.. (2015). Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System. Journal of Managed Care & Specialty Pharmacy. 21(10). 863–871b. 39 indexed citations
16.
17.
Rashid, Nazia, et al.. (2014). Patterns and Predictors of First-Line Therapy Use Among Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant in an Integrated Healthcare System. 10(1). 1 indexed citations
18.
Niihara, Yutaka, Han Koh, Lan Tran, et al.. (2014). A Phase 3 Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia. Blood. 124(21). 86–86. 23 indexed citations
19.
Cortés, Javier, Joyce O’Shaughnessy, David Loesch, et al.. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 377(9769). 914–923. 807 indexed citations breakdown →
20.
Giles, Francis J., et al.. (1997). Skin Necrosis Associated With Heparin-Induced Thrombocytopenia and Thrombosis. Hematology. 2(2). 169–177.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nawel Bourayou Breakdown of academic impact, for papers by Janice M. Walshe Breakdown of academic impact, for papers by Susana Barriga Breakdown of academic impact, for papers by Katarína Petráková Breakdown of academic impact, for papers by Olga Burdaeva Breakdown of academic impact, for papers by Meena Okera Breakdown of academic impact, for papers by Martin Frenzel Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Gail S. Wright
Rankless by CCL
2026